Eli Lilly Partners With Amgen to Manufacture Potential COVID-19 Antibody

Eli Lilly has entered into a global partnership with Amgen to increase supply capacity for Eli Lilly’s neutralizing antibodies as a treatment for COVID-19 patients.

The partnership will allow Eli Lilly to scale up production of the potential therapies should one of its antibodies be approved. The companies said they expect to be able to produce millions of doses of the antibodies as early as next year.

Eli Lilly yesterday reported that a single dose of its lead monoclonal antibody LY-CoV-555 reduced hospitalization rates in COVID-19 patients by 72 percent.